Raymond James Initiates Coverage On Kymera Therapeutics with Outperform Rating, Announces Price Target of $140

Raymond James analyst Thomas Deal has initiated coverage on Kymera Therapeutics (NASDAQ: KYMR) with an Outperform rating. The firm has set a price target of $140 for the company's stock.